期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 52, 期 8, 页码 2571-2586出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm900044w
关键词
-
资金
- companies of the Industrial Macromolecular Crystallography Association through a contract with Illinois Institute of Technology (IIT)
- U.S. Department of Energy, Basic Energy Sciences, Office of Science [W-31-109-Eng-38]
A series of symmetry-based HIV protease inhibitors was designed and synthesized. Modification of the core regiochemistry and stereochemistry significantly affected the potency, metabolic stability, and oral bioavailability of the inhibitors, as did the variation of a pendent arylmethyl P3 group. Optimization led to the selection of two compounds, 10c (A-790742) and 9d (A-792611), for advancement to preclinical studies. Both compounds displayed low nanomolar potency against wild type HIV in the presence of human serum, low rates of metabolism in human liver microsomes, and high oral bioavailability in animal models. The compounds were examined in a preclinical model for the hyperbilirubinemia observed with some HIV PIs, and both exhibited less bilirubin elevation than comparator compounds. X-ray crystallographic analyses of the new cores were used to examine differences in their binding modes. The antiviral activity of the compounds against protease inhibitor resistant strains of HIV was also determined.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据